[Pulmonary manifestations induced by osimertinib].
Sign Up to like & getrecommendations! Published in 2021 at "Revue des maladies respiratoires"
DOI: 10.1016/j.rmr.2021.12.002
Abstract: INTRODUCTION The third-generation tyrosine kinase inhibitor (TKI) osimertinib is recommended as a first-line treatment in advanced non-small cell lung cancer harboring an activating mutation of Epidermal Growth Factor Receptor (EGFR). Adverse pulmonary events related to… read more here.
Keywords: induced osimertinib; lung; pulmonary manifestations; manifestations induced ... See more keywords